Key Highlights
- Net loss was USD 3.33 million, compared with USD 1.43 million.
- Loss per share was USD 0.07, against USD 0.03.
- Research and development expenses were USD 2.45 million, against USD 514 thousand.
- Cash and cash equivalents were USD 8.44 million at September 30.
Polaryx Therapeutics (NASDAQ:PLYX) reported a third quarter 2026 net loss and comprehensive loss of USD 3.33 million, compared with USD 1.43 million in the third quarter of 2025. Basic and diluted net loss per share was USD 0.07, compared with USD 0.03.
The operating loss was USD 3.33 million, compared with USD 974 thousand. The company reported the figures in its quarterly filing for the period ended September 30, 2026.
Operating Expenses
Research and development expenses were USD 2.45 million, compared with USD 514 thousand, and general and administrative expenses were USD 877 thousand, compared with USD 460 thousand. Total operating expenses were USD 3.33 million, compared with USD 974 thousand.
The prior-year quarter included other expense of USD 456 thousand for direct listing offering costs, with none in the third quarter of 2026. Weighted average common shares outstanding, basic and diluted, were 49,845,993, compared with 45,792,898.
Nine-Month Results
For the nine months ended September 30, 2026, the net loss was USD 7.25 million, compared with USD 7.49 million, and the net loss per share was USD 0.15, compared with USD 0.17. Total operating expenses were USD 6.67 million, compared with USD 6.91 million, and the operating loss was USD 6.67 million, compared with USD 6.91 million.
Research and development expenses for the nine months were USD 3.85 million, compared with USD 5.71 million, and general and administrative expenses were USD 2.82 million, compared with USD 1.20 million. Other expense for direct listing offering costs was USD 586 thousand, compared with USD 580 thousand.
Balance Sheet and Pipeline
Cash and cash equivalents were USD 8.44 million, compared with USD 5.14 million at the prior Balance Sheet date, and prepaid expenses were USD 152 thousand. Total Assets were USD 8.61 million, compared with USD 5.17 million, and total liabilities were USD 999 thousand, compared with USD 605 thousand. Accounts Payable were USD 783 thousand, compared with USD 470 thousand.
The filing states that the company's most advanced product candidate, PLX-200, is an oral, repurposed small molecule that targets several lysosomal storage disorders, and that it intends to launch a Phase 2 proof-of-concept basket trial. It describes PLX-300 as a novel, oral small molecule therapy in studies enabling an investigational new drug application, PLX-100 as a preclinical combination therapy, and PLX-400 as a preclinical gene therapy for lysosomal storage disorders.
Weighted average common shares outstanding for the nine months were 48,457,518. The filing also reports Research and Development expenses excluding Stock Compensation of USD 2.45 million for the quarter, compared with USD 514 thousand, and USD 3.85 million for the nine months, compared with USD 1.36 million. Other current assets were USD 18 thousand, compared with USD 27 thousand.
Polaryx Therapeutics Q3 2026 Earnings: Key Takeaways
Polaryx Therapeutics reported a third quarter 2026 net loss of USD 3.33 million and a loss per share of USD 0.07. Research and development expenses were USD 2.45 million, and cash and cash equivalents were USD 8.44 million.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...